[{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||4-1BB\/CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||4-1BB\/CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"4-1BB\/CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"A.A. Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Tissue Engineered Bone Equivalent","moa":"Bone tissue","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"A.A. Partners","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"A.A. Partners \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"A.A. Partners \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Osteochondral Allograft","moa":"Cartilage\/bone repair","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Osteochondral Allograft","moa":"Cartilage\/bone repair","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CABA-201","moa":"CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Synartro AB","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Synartro AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Synartro AB \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"7","companyTruncated":"Synartro AB \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Nordic Bioscience Clinical Development","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Nordic Bioscience Clinical Development","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Nordic Bioscience Clinical Development"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Private Placement","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spherium Biomed","sponsor":"Universitat Internacional de Catalunya | Hospital Odontol\u00f2gic UB | Hospital Universitario La Fe | Hospital Universitario Rey Juan Carlos","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Spherium Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Powder","sponsorNew":"Spherium Biomed \/ Universitat Internacional de Catalunya | Hospital Odontol\u00f2gic UB | Hospital Universitario La Fe | Hospital Universitario Rey Juan Carlos","highestDevelopmentStatusID":"7","companyTruncated":"Spherium Biomed \/ Universitat Internacional de Catalunya | Hospital Odontol\u00f2gic UB | Hospital Universitario La Fe | Hospital Universitario Rey Juan Carlos"},{"orgOrder":0,"company":"QC Kinetix LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"QC Kinetix LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QC Kinetix LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"QC Kinetix LLC \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Dynacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2 messenger RNA (DNM2 mRNA)","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dynacure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Undisclosed"},{"orgOrder":0,"company":"Dynacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2 messenger RNA (DNM2 mRNA)","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dynacure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Undisclosed"},{"orgOrder":0,"company":"Dynacure","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"DYN101","moa":"DNM2 messenger RNA (DNM2 mRNA)","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dynacure \/ Nippon Shinyaku","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Dynacure","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Series C Financing","leadProduct":"DYN101","moa":"DNM2 messenger RNA (DNM2 mRNA)","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Dynacure \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Perceptive Advisors"},{"orgOrder":0,"company":"Dynacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2 messenger RNA (DNM2 mRNA)","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dynacure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Undisclosed"},{"orgOrder":0,"company":"Dynacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"DYN-101","moa":"DNM2 pre-mRNA","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynacure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Undisclosed"},{"orgOrder":0,"company":"Dynacure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DYN-101","moa":"DNM2 pre-mRNA","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynacure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Undisclosed"},{"orgOrder":0,"company":"SpineThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpineThera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Undisclosed"},{"orgOrder":0,"company":"SpineThera","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"SpineThera \/ Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Department of Defense"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Dystonia Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Dystonia Study Group","highestDevelopmentStatusID":"7","companyTruncated":"University Health Network, Toronto \/ Dystonia Study Group"},{"orgOrder":0,"company":"Histogen","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"HST-003","moa":"Hyaline cartilage","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ US Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ US Department of Defense"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10R","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xalud Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xalud Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Xindu Pty Ltd","sponsor":"Xintela AB","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XSTEM-OA","moa":"Immune","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Xindu Pty Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xindu Pty Ltd \/ Xintela AB","highestDevelopmentStatusID":"7","companyTruncated":"Xindu Pty Ltd \/ Xintela AB"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"2ccPA","moa":"Lysophosphatidic acid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"2ccPA","moa":"Lysophosphatidic acid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"FPA008","moa":"Macrophage colony stimulating factor receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Five Prime Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Five Prime Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":3,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":3,"dosageForm":"Infusion","sponsorNew":"Audentes Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Audentes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Audentes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ICM Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ICM-203","moa":"NKX3-2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"ICM Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"ICM Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ICM Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"ICM Biotech Australia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"ICM-203","moa":"NKX3-2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"ICM Biotech Australia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"ICM Biotech Australia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ICM Biotech Australia \/ Undisclosed"},{"orgOrder":0,"company":"Translational Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Autologous Adipose Tissue Stromal Vascular Fraction","moa":"Progenitor cell","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Translational Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Translational Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Taipei Veterans General Hospital","sponsor":"Virginia Contract Research Organization","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Allogenic Bone Marrow Derived Mesenchymal Stem Cell","moa":"Progenitor cell||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Taipei Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taipei Veterans General Hospital \/ Virginia Contract Research Organization","highestDevelopmentStatusID":"7","companyTruncated":"Taipei Veterans General Hospital \/ Virginia Contract Research Organization"},{"orgOrder":0,"company":"Next Generation Regenerative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bone Marrow-Derived Mesenchymal Stem Cell","moa":"Progenitor cell","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Next Generation Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Next Generation Regenerative Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Next Generation Regenerative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"li nguyen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gadolinium","moa":"Ribonucleoside-diphosphate reductase RR1 | Thioredoxin reductase 1","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"li nguyen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"li nguyen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"li nguyen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Thomas J. Schnitzer","sponsor":"Nuvo Research Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Thomas J. Schnitzer","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas J. Schnitzer \/ Nuvo Research Inc","highestDevelopmentStatusID":"7","companyTruncated":"Thomas J. Schnitzer \/ Nuvo Research Inc"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"CEP-37247","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CDA Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"3VM1001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"CDA Research Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDA Research Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CDA Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Nova Vita Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Allogenic Human Amniotic Fluid","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nova Vita Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Vita Laboratories \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nova Vita Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Cytori Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Adrcs","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cytori Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytori Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cytori Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fundaci\u00f3n Oftalmol\u00f3gica de Santander","sponsor":"Cells for Cells","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"COLOMBIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Cell Therapy","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Fundaci\u00f3n Oftalmol\u00f3gica de Santander","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fundaci\u00f3n Oftalmol\u00f3gica de Santander \/ Cells for Cells","highestDevelopmentStatusID":"7","companyTruncated":"Fundaci\u00f3n Oftalmol\u00f3gica de Santander \/ Cells for Cells"},{"orgOrder":0,"company":"Longeveron","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Allogeneic Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ The Emmes Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Longeveron \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Red de Terapia Celular","sponsor":"University of Valladolid | Sanidad de Castilla y Le\u00f3n | Centro M\u00e9dico Teknon","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Allogenic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Red de Terapia Celular","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Red de Terapia Celular \/ University of Valladolid | Sanidad de Castilla y Le\u00f3n | Centro M\u00e9dico Teknon","highestDevelopmentStatusID":"7","companyTruncated":"Red de Terapia Celular \/ University of Valladolid | Sanidad de Castilla y Le\u00f3n | Centro M\u00e9dico Teknon"},{"orgOrder":0,"company":"Tetec AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Disc Chondrocytes","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Tetec AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetec AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tetec AG \/ Undisclosed"},{"orgOrder":0,"company":"University of Science Ho Chi Minh City","sponsor":"GeneWorld Co., Ltd. | Van Hanh General Hospital | 115 People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"VIETNAM","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Autologous Stromal Vascular Fraction","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"University of Science Ho Chi Minh City","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Science Ho Chi Minh City \/ GeneWorld Co., Ltd. | Van Hanh General Hospital | 115 People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"University of Science Ho Chi Minh City \/ GeneWorld Co., Ltd. | Van Hanh General Hospital | 115 People's Hospital"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Axolotl Ambient","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axolotl Biologix \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Axolotl Biologix \/ Undisclosed"},{"orgOrder":0,"company":"BIONCaRT GmbH","sponsor":"KKS Netzwerk | Fraunhofer Institute for Cell Therapy and Immunology IZI | Polski Bank Komorek Macierzystych JSC","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BP CC 001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"BIONCaRT GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIONCaRT GmbH \/ KKS Netzwerk | Fraunhofer Institute for Cell Therapy and Immunology IZI | Polski Bank Komorek Macierzystych JSC","highestDevelopmentStatusID":"7","companyTruncated":"BIONCaRT GmbH \/ KKS Netzwerk | Fraunhofer Institute for Cell Therapy and Immunology IZI | Polski Bank Komorek Macierzystych JSC"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BSL_EP028","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Connext","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CNT201","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Connext","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connext \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connext \/ Undisclosed"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Furestem-OA","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"FX005","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Gwo Xi Stem Cell Applied Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GXCPC1","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Gwo Xi Stem Cell Applied Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gwo Xi Stem Cell Applied Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gwo Xi Stem Cell Applied Technology \/ Undisclosed"},{"orgOrder":0,"company":"Cellcolabs Clinical LTD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cellcolabs Clinical LTD.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellcolabs Clinical LTD. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellcolabs Clinical LTD. \/ Undisclosed"},{"orgOrder":0,"company":"Cellcolabs Clinical SPV Limited","sponsor":"PDC-CRO","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cellcolabs Clinical SPV Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellcolabs Clinical SPV Limited \/ PDC-CRO","highestDevelopmentStatusID":"7","companyTruncated":"Cellcolabs Clinical SPV Limited \/ PDC-CRO"},{"orgOrder":0,"company":"Cellcolabs Clinical LTD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cellcolabs Clinical LTD.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellcolabs Clinical LTD. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellcolabs Clinical LTD. \/ Undisclosed"},{"orgOrder":0,"company":"Translational Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Translational Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Translational Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Undisclosed"},{"orgOrder":0,"company":"Immunis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Undisclosed"},{"orgOrder":0,"company":"Immunis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Undisclosed"},{"orgOrder":0,"company":"Immunis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Undisclosed"},{"orgOrder":0,"company":"Immunis","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series A Financing","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Immunis \/ Remiges Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Remiges Ventures"},{"orgOrder":0,"company":"Immunis","sponsor":"Springbok","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunis \/ Springbok","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Springbok"},{"orgOrder":0,"company":"Immunis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LG00034053","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Powder","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Elpida Therapeutics","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Melpida Gene Therapy","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Elpida Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpida Therapeutics \/ UT Southwestern Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Elpida Therapeutics \/ UT Southwestern Medical Center"},{"orgOrder":0,"company":"Shanghai AbelZeta Ltd.","sponsor":"RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Shanghai AbelZeta Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai AbelZeta Ltd. \/ RenJi Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai AbelZeta Ltd. \/ RenJi Hospital"},{"orgOrder":0,"company":"Akanbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Akanbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akanbio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Akanbio \/ Undisclosed"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Mesenchymal-Like Adherent Stromal Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Shanghai 6th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Shanghai 6th People's Hospital | Beijing Luhe Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NCR100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital | Beijing Luhe Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital | Beijing Luhe Hospital"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NCR100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuwacell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"NVD-001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"NVD-X3","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Cell Therapy","sponsor":"The Institute of Traumatology and Orthopedics of NAMS of Ukraine | Kyiv City Clinical Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UKRAINE","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Placenta-Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Institute of Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Cell Therapy \/ The Institute of Traumatology and Orthopedics of NAMS of Ukraine | Kyiv City Clinical Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Institute of Cell Therapy \/ The Institute of Traumatology and Orthopedics of NAMS of Ukraine | Kyiv City Clinical Hospital"},{"orgOrder":0,"company":"RepliCel","sponsor":"Syreon Corporation | Innovacell Biotechnologie","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"RCT-01","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"RepliCel","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RepliCel \/ Syreon Corporation | Innovacell Biotechnologie","highestDevelopmentStatusID":"7","companyTruncated":"RepliCel \/ Syreon Corporation | Innovacell Biotechnologie"},{"orgOrder":0,"company":"DePuy Spine","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human GDF-5","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"DePuy Spine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"DePuy Spine \/ Janssen-Cilag","highestDevelopmentStatusID":"7","companyTruncated":"DePuy Spine \/ Janssen-Cilag"},{"orgOrder":0,"company":"DePuy Spine","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human GDF-5","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"DePuy Spine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"DePuy Spine \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"DePuy Spine \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Recombinant Human Parathyroid Hormone (1-34)","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Undisclosed"},{"orgOrder":0,"company":"Cellcolabs Clinical SPV Limited","sponsor":"PDC-CRO","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Stromaforte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cellcolabs Clinical SPV Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellcolabs Clinical SPV Limited \/ PDC-CRO","highestDevelopmentStatusID":"7","companyTruncated":"Cellcolabs Clinical SPV Limited \/ PDC-CRO"},{"orgOrder":0,"company":"PT Prodia StemCell Indonesia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDONESIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"PT Prodia StemCell Indonesia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT Prodia StemCell Indonesia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PT Prodia StemCell Indonesia \/ Undisclosed"},{"orgOrder":0,"company":"Translational Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Translational Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Translational Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BioIntegrate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"BioIntegrate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioIntegrate \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioIntegrate \/ Undisclosed"},{"orgOrder":0,"company":"BioIntegrate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"BioIntegrate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioIntegrate \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioIntegrate \/ Undisclosed"},{"orgOrder":0,"company":"YooYoung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"YY1201","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"YooYoung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"YooYoung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"Vanilloid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"VitalgNetics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ VitalgNetics","highestDevelopmentStatusID":"7","companyTruncated":"Vedic Lifesciences \/ VitalgNetics"},{"orgOrder":0,"company":"Calosyn Pharma","sponsor":"Health Decisions","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Verapamil","moa":"Voltage-gated L-type calcium channel","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Calosyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calosyn Pharma \/ Health Decisions","highestDevelopmentStatusID":"7","companyTruncated":"Calosyn Pharma \/ Health Decisions"},{"orgOrder":0,"company":"Ankasa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ART352-L","moa":"WNT3A","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Ankasa","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankasa \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ankasa \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Amir Oron","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"Enlivex Therapeutics \/ Amir Oron","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Amir Oron"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
